13F filerCIK 1061768 ↗

Baupost Group

You are looking at Q2 2016. See the latest, Q3 2026 →

Reported value

$7.37B

+6.4% on the quarter before

Positions

39

10 new, 7 sold out

Top 10

74.5%

of the value

Est. gain

+$94.5M

on stocks held all quarter

Est. return

+1.5%

on those stocks since Q1 2016

Filed

Aug 12, 2016

On SEC EDGAR ↗

Positions as of Jun 30, 2016, from Baupost Group's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

  • New
  • Added
  • Cut
  • Same
  • Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q1 2016. Striped tiles are options.

E M C Corp Mass21%
Cheniere Energy Inc15%
Viasat Inc11%
Allergan Plc6.3%
Antero Res Corp5.1%
15 others4.2%
Olin Corp3.6%
Pbf Energy Inc3.4%
Citigroup Inc3.0%
Twenty First Centy Fox Inc2.8%
PayPal2.8%
Twenty First Centy Fox Inc2.7%
Innoviva Inc2.5%
Keryx Biopharmaceuticals Inc2.3%
Theravance Biopharma Inc2.3%
Vmware Inc1.7%
Atara Biotherapeutics Inc1.6%
Veritiv Corp1.6%
Forward Pharma A/S1.3%
Liberty Interactive Corp1.2%
Chipmos Tech Bermuda Ltd0.9%
0.8%
0.8%
0.8%
0.7%

Largest buys

Since Q1 2016, sized at quarter-end prices.

  1. Citigroup Inc~$219.0MNew, 0.0% → 3.0% of the portfolio+5,167,000 shares
  2. E M C Corp Mass~$138.8MAdded, 20.0% → 21.0% of the portfolio+5,110,225 shares
  3. Liberty Interactive Corp~$91.5MNew, 0.0% → 1.2% of the portfolio+2,469,533 shares
  4. Allergan Plc~$64.8MAdded, 6.7% → 6.3% of the portfolio+280,391 shares
  5. Avis Budget Group~$57.6MNew, 0.0% → 0.8% of the portfolio+1,787,227 shares
  6. Liberty Media Corp Delaware~$43.9MNew, 0.0% → 0.6% of the portfolio+2,994,010 shares
  7. Silver Run Acquisition Corp~$36.8MNew, 0.0% → 0.5% of the portfolio+3,750,000 shares
  8. Cascadian Therapeutics Inc~$23.6MNew, 0.0% → 0.3% of the portfolio+25,000,000 shares
  9. Theravance Biopharma Inc~$19.3MAdded, 1.8% → 2.3% of the portfolio+850,000 shares
  10. Credit Accep Corp Mich~$18.5MNew, 0.0% → 0.3% of the portfolio+100,000 shares

Largest sells

Since Q1 2016, sized at quarter-end prices.

  1. Antero Res Corp~$181.9MCut, 7.7% → 5.1% of the portfolio−7,000,000 shares
  2. PayPal~$51.0MCut, 3.9% → 2.8% of the portfolio−1,395,658 shares
  3. Silver Run Acquisition Corp~$38.8MSold out, 0.6% → 0.0% of the portfolio−3,750,000 shares
  4. Biotie Therapies Oyj~$36.8MSold out, 0.5% → 0.0% of the portfolio−1,395,000 shares
  5. Novagold Res Inc~$33.7MCut, 1.1% → 0.8% of the portfolio−5,500,000 shares
  6. Innoviva Inc~$23.2MCut, 3.6% → 2.5% of the portfolio−2,205,892 shares
  7. Chesapeake Energy Corp~$14.7MSold out, 0.2% → 0.0% of the portfolio−23,300,000 shares
  8. La Quinta Hldgs Inc~$13.9MSold out, 0.2% → 0.0% of the portfolio−1,111,000 shares
  9. Bellatrix Exploration Ltd~$8.7MSold out, 0.1% → 0.0% of the portfolio−8,653,281 shares
  10. Chesapeake Energy Corp~$7.3MSold out, 0.1% → 0.0% of the portfolio−11,500,000 shares

Holdings

As of Jun 30, 2016; changes in shares since Mar 31, 2016.

Positions, sorted by share of the portfolio
HoldingValue
E M C Corp MassCOM · shares +9.9% · price +2.0%21.0%$1.55B+$27.0M
Cheniere Energy IncCOM NEW · shares 0% · price +11.0%15.2%$1.12B+$111.0M
Viasat IncCOM · shares 0% · price −2.8%11.2%$823.5M−$24.0M
Allergan PlcSHS · shares +16% · price −13.8%6.3%$462.6M−$63.6M
Antero Res CorpCOM · shares −33% · price +4.5%5.1%$376.9M+$16.1M
Olin CorpCOM PAR $1 · shares 0% · price +43.0%3.6%$266.8M+$80.2M
Pbf Energy IncCL A · shares 0% · price −28.4%3.4%$253.0M−$100.2M
Citigroup IncCOM NEW · shares New3.0%$219.0M—
Twenty First Centy Fox IncCL A · shares 0% · price −3.0%2.8%$208.2M−$6.4M
PayPalCOM · shares −20% · price −5.4%2.8%$206.8M−$11.8M
Twenty First Centy Fox IncCL B · shares 0% · price −3.4%2.7%$198.3M−$6.9M
Innoviva IncCOM · shares −11% · price −16.4%2.5%$185.4M−$36.3M
Keryx Biopharmaceuticals IncCOM · shares 0% · price +41.8%2.3%$170.7M+$50.3M
Theravance Biopharma IncCOM · shares +13% · price +20.7%2.3%$166.8M+$25.3M
Vmware IncCL A COM · shares 0% · price +9.4%1.7%$128.9M+$11.1M
Atara Biotherapeutics IncCOM · shares 0% · price +18.3%1.6%$120.6M+$18.7M
Veritiv CorpCOM · shares 0% · price +0.9%1.6%$114.4M+$974,000
Forward Pharma A/SSPONSORED ADR · shares 0% · price +6.9%1.3%$97.5M+$6.3M
Liberty Interactive CorpLBT VENT COM A · shares New1.2%$91.5M—
Chipmos Tech Bermuda LtdSHS · shares 0% · price +4.2%0.92%$67.9M+$2.7M
Klx IncCOM · shares 0% · price −3.5%0.84%$62.0M−$2.3M
Novagold Res IncCOM NEW · shares −37% · price +21.4%0.79%$58.1M+$10.3M
Avis Budget GroupCOM · shares New0.78%$57.6M—
Sunedison Semiconductor LtdSHS · shares 0% · price −8.5%0.67%$49.7M−$4.6M
American Intl Group Inc*W EXP 01/19/202 · shares +20% · price −0.1%0.65%$47.7M−$20,841
Total 39 positions100%$7.37B+$94.5M

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q1 2016 to Q2 2016: 28 stocks held throughout, up $94.5M (+1.5%).

  1. Cheniere Energy Inc+$111.0M+11%
  2. Olin Corp+$80.2M+43%
  3. Keryx Biopharmaceuticals Inc+$50.3M+42%
  4. E M C Corp Mass+$27.0M+2%
  5. Theravance Biopharma Inc+$25.3M+21%
  6. PayPal−$11.8M−5%
  7. Viasat Inc−$24.0M−3%
  8. Innoviva Inc−$36.3M−16%
  9. Allergan Plc−$63.6M−14%
  10. Pbf Energy Inc−$100.2M−28%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

Pick a quarter to see what the fund held then.

$20.00B$10.00B$0
Q1 2016Q3 2026
Every quarter's filing
Each quarter's 13F filing, newest first
QuarterReported valueFiling
Q3 2026$5.05B−7%SEC ↗
Q2 2026$5.42B+6%SEC ↗
Q1 2026$5.12B−3%SEC ↗
Q4 2025$5.28B+10%SEC ↗
Q3 2025$4.79B+16%SEC ↗
Q2 2025$4.13B+18%SEC ↗
Q1 2025$3.50B+2%SEC ↗
Q4 2024$3.43B−2%SEC ↗
Q3 2024$3.52B−3%SEC ↗
Q2 2024$3.63B−0%SEC ↗
Q1 2024$3.65B−20%SEC ↗
Q4 2023$4.59B−12%SEC ↗
Q3 2023$5.21B−7%SEC ↗
Q2 2023$5.61B−4%SEC ↗
Q1 2023$5.85B−5%SEC ↗
Q4 2022$6.13B+6%SEC ↗
Q3 2022$5.79B−14%SEC ↗
Q2 2022$6.77B−27%SEC ↗
Q1 2022$9.30B−8%SEC ↗
Q4 2021$10.13B−7%SEC ↗
Q3 2021$10.88B−12%SEC ↗
Q2 2021$12.33B−2%SEC ↗
Q1 2021$12.56B+16%SEC ↗
Q4 2020$10.84B+17%SEC ↗
Q3 2020$9.25B+15%SEC ↗
Q2 2020$8.01B+18%SEC ↗
Q1 2020$6.77B−25%SEC ↗
Q4 2019$9.06B+3%SEC ↗
Q3 2019$8.83B−20%SEC ↗
Q2 2019$11.05B−7%SEC ↗
Q1 2019$11.90B+3%SEC ↗
Q4 2018$11.52B−12%SEC ↗
Q3 2018$13.06B+14%SEC ↗
Q2 2018$11.44B+10%SEC ↗
Q1 2018$10.37B+3%SEC ↗
Q4 2017$10.11B+26%SEC ↗
Q3 2017$8.02B−8%SEC ↗
Q2 2017$8.75B+3%SEC ↗
Q1 2017$8.49B+11%SEC ↗
Q4 2016$7.67B+9%SEC ↗
Q3 2016$7.04B−4%SEC ↗
Q2 2016$7.37B+6%SEC ↗
Q1 2016$6.92BSEC ↗

Subscribe to TheInference for free